PMV Pharma finalizes $50.8 million offering, details rezatapopt data and NDA timelineSep 1FinancingPMV Pharmaceuticals, Increzatapopt
PMV Pharma reports 46% ORR in ovarian cancer cohort of rezatapopt trialAug 31Regulatory decisionPMV Pharmaceuticals, Increzatapopt
PMV Pharma completes PYNNACLE enrollment, targets Q1 2027 NDA for rezatapoptAug 14Quarterly updatePMV Pharmaceuticals, Increzatapopt
Sign inSign in